This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.

In this video, David takes a closer look at two biotechs considered takeover targets. In fact, Amylin recently rebuffed an offer from Bristol-Myers Squibb. Will the large pharma come back with a stronger offer or will another player emerge from the shadows with a deal Amylin can't refuse? Meanwhile, Amarin recieved a patent for its cholesterol-fighting fish-oil-based drug AMR-101, which is pending FDA approval after two successful phase 3 trials. With patent protection in hand and potentially an approval on its way, will a deep-pocketed player with a thin pipeline step up to the plate, or will Amarin attempt to go it alone? Watch and find out.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.